Literature DB >> 731241

Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.

A Rappelli, N Glorioso, R Tedde, P Dessi'-Fulgheri, F Monaco.   

Abstract

Plasma renin activity (PRA) of patients with Parkinson's disease was measured in recumbency, upright position, and after frusemide administration. The results show that the renin responses to both stimuli are significantly reduced as compared with those obtained in a group of normal subjects, while recumbent PRA levels of Parkinsonism patients are not significantly lower than those found in recumbent normal subjects. Levodopa treatment, alone or in combination with two different dopa-decarboxylase inhibitors, benserazide and carbidopa, does not modify the renin response to posture or to frusemide. Although the reduced activity of the renin-angiotensin system can play some role in the genesis of orthostatic hypotensive episodes encountered in patients with Parkinsonism, the greater incidence of orthostatis hypotension in patients treated with levodopa seems to be unrelated to any effect of this drug on the renin release.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 731241      PMCID: PMC493194          DOI: 10.1136/jnnp.41.10.915

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

1.  Noradrenaline: central inhibitory control of blood pressure and heart rate.

Authors:  W De Jong
Journal:  Eur J Pharmacol       Date:  1974-11       Impact factor: 4.432

2.  Evidence for a centrally mediated hypotensive effect of L-dopa in the rat.

Authors:  M Henning; A Rubenson
Journal:  J Pharm Pharmacol       Date:  1970-03       Impact factor: 3.765

3.  The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary.

Authors:  R E Keenan
Journal:  Neurology       Date:  1970-12       Impact factor: 9.910

4.  Plasma renin activity and levodopa in Parkinson's disease.

Authors:  A M Michelakis; D Robertson
Journal:  JAMA       Date:  1970-07-06       Impact factor: 56.272

5.  Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.

Authors:  M Leibowitz; A Lieberman
Journal:  Neurology       Date:  1975-10       Impact factor: 9.910

6.  Renin-aldosterone system in Parkinson's disease.

Authors:  A Barbeau; L Gillo-Joffroy; R Boucher; W Nowaczynski; J Genest
Journal:  Science       Date:  1969-07-18       Impact factor: 47.728

7.  Centrally mediated decrease in sympathetic tone induced by 2(2,6-dichlorophenylamino)-2 imidazoline (S.T. 155, Catapresan).

Authors:  H Schmitt; J R Boissier; J F Giudicelli
Journal:  Eur J Pharmacol       Date:  1967-11       Impact factor: 4.432

  7 in total
  3 in total

1.  Autonomic Nervous System Dysfunction in Parkinson's Disease.

Authors:  Theresa A. Zesiewicz; Matthew J. Baker; Mervat Wahba; Robert A. Hauser
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

2.  The use of bromocriptine for testing central dopaminergic reactivity.

Authors:  H Allain; J M Reymann; D Bentue-Ferrer; D Pape; J van den Driessche; O Sabouraud
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

3.  The management of orthostatic hypotension in Parkinson's disease.

Authors:  Alvaro Sánchez-Ferro; Julián Benito-León; Juan Carlos Gómez-Esteban
Journal:  Front Neurol       Date:  2013-06-10       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.